Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells by Dolfi, Sonia C. et al.
Oncotarget44639www.impactjournals.com/oncotarget
Riluzole exerts distinct antitumor effects from a metabotropic 
glutamate receptor 1-specific inhibitor on breast cancer cells
Sonia C. Dolfi1, Daniel J. Medina1, Aparna Kareddula1, Bhavna Paratala1, Ashley 
Rose1, Jatinder Dhami1, Suzie Chen2, Shridar Ganesan1, Gillian Mackay3, Alexei 
Vazquez3 and Kim M. Hirshfield1
1Department of Medicine, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New 
Brunswick, New Jersey 08901, USA
2Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, 
Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA
3CRUK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK
Correspondence to: Kim M. Hirshfield, email: hirshfie@cinj.rutgers.edu
Keywords: riluzole, breast cancer, glutamate signaling, cell cycle, BAY 36-7620
Received: September 09, 2016    Accepted: April 20, 2017    Published: May 18, 2017
Copyright: Dolfi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited. 
ABSTRACT
Recent evidence suggests that glutamate signaling plays an important role 
in cancer. Riluzole is a glutamate release inhibitor and FDA-approved drug for the 
treatment of amyotrophic lateral sclerosis. It has been investigated as an inhibitor 
of cancer cell growth and tumorigenesis with the intention of repurposing it for the 
treatment of cancer. Riluzole is thought to act by indirectly inhibiting glutamate 
signaling. However, the specific effects of riluzole in breast cancer cells are not well 
understood. In this study, the anti-cancer effects of riluzole were explored in a panel 
of breast cancer cell lines in comparison to the metabotropic glutamate receptor 
1-specific inhibitor BAY 36-7620. While both drugs inhibited breast cancer cell 
proliferation, there were distinct functional effects suggesting that riluzole action 
may be metabotropic glutamate receptor 1-independent. Riluzole induced mitotic 
arrest independent of oxidative stress while BAY 36-7620 had no measurable effect on 
mitosis. BAY 36-7620 had a more pronounced and significant effect on DNA damage 
than riluzole. Riluzole altered cellular metabolism as demonstrated by changes in 
oxidative phosphorylation and cellular metabolite levels. These results provide a 
better understanding of the functional action of riluzole in the treatment of breast 
cancer.
INTRODUCTION
Although glutamate signaling was initially 
characterized in central nervous system (CNS) 
development and synaptic transmission, its importance 
in tumorigenesis in multiple organs is becoming better 
defined [1–6]. Breast, melanoma, and prostate cancer 
cell lines and human prostate tumors have been shown 
to release glutamate [7, 8] as well as express glutamate 
receptors [9]. Efforts have focused on targeting 
ionotropic and metabotropic glutamate receptors and 
their downstream pathways as an anti-cancer therapeutic 
strategy. Ionotropic glutamate receptors are ligand-gated 
ion channels and contain four classes of receptors (AMPA, 
NMDA, kainate, and delta receptors). Metabotropic 
glutamate receptors, a family of seven-transmembrane G 
protein-coupled receptors, are divided into three groups 
based on sequence homology and functional similarities. 
Metabotropic glutamate receptor 1 (GRM1), a member of 
group I, regulates synaptic signaling in the CNS. At least 
four GRM1 variants (mGluR1a, b, d, and g) have been 
detected due to alternative splicing of the gene transcript, 
and they encode for proteins with 1195, 906, 908, and 
887 amino acids, respectively. All variants share the first 
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886 N-terminal amino acids but have distinct C-terminal 
regions.
Though GRM1 was initially functionally 
characterized in CNS biology, its importance in 
tumorigenesis in organ systems outside of the CNS has 
become better defined. GRM1 was first recognized for 
its oncogenic potential after a transgenic mouse model 
presented with spontaneous melanomas [10]. This resulted 
because of a transgene insertion into intron 3 of GRM1 
leading to ectopic GRM1 expression. Activation of GRM1 
by its natural ligand glutamate or glutamate receptor 
agonists alters its interactions with G proteins. These 
interactions lead to stimulation of second messengers and 
induction of protein kinase C (PKC) and phospholipase 
C (PLC) and intracellular calcium release with resultant 
activation of mitogen-activated protein kinase (MAPK) 
and Akt pathways.
As the drug riluzole blocks glutamate release 
[11, 12], it indirectly affects glutamate signaling by 
both autocrine and paracrine actions. In vitro data with 
melanoma cells suggest that riluzole causes increased 
intracellular glutamate levels under glutamate and 
glutamine-free conditions [13]. Exchange of intracellular 
glutamate for extracellular cystine occurs through the 
action of the x-C-type transporter (xCT). As the precursor 
of intracellular cysteine, cystine is necessary to replenish 
glutathione. Thus, it follows that riluzole treatment could 
lead to increased oxidative stress, DNA damage, and 
cell death. Similar mechanisms have not been evaluated 
for the noncompetitive GRM1 inhibitor BAY 36-7620 
where BAY 36-7620-induced receptor inhibition results 
in reduced glutamate release [14]. Therefore, if the 
functional mechanism of both drugs is through inhibition 
of glutamate release and glutamate signaling through 
GRM1, then functional effects would also be similar.
Both riluzole and BAY 36-7620 negatively regulate 
the MAPK and Akt signaling pathways in melanoma cell 
lines, effectively inhibiting cell growth, proliferation, and 
invasion [14–16]. A phase 0/I trial of riluzole in patients 
with stage III/IV melanoma demonstrated a correlation 
between reduced extracellular signal–regulated kinase 
(ERK) and Akt phosphorylation with reduction in tumor 
size [17]. Additionally, combined riluzole and ionizing 
radiation treatment in GRM1-expressing melanoma cell 
lines and melanoma xenografts in mice yielded synergistic 
suppression of cell growth and tumor progression as 
compared to radiation alone [18, 19].
Growing evidence supports the role of glutamate 
signaling in breast cancer. Consistent with higher GRM1 
expression in malignant as compared to normal prostate 
tissue [20], a significantly higher fraction of human breast 
tumors express GRM1 as compared to normal breast tissue 
[1]. Moreover, treatment of estrogen receptor positive 
(ER+) MCF-7 xenografts with riluzole alone and with 
an Akt inhibitor suppresses tumor growth in vivo [21]. 
Others have also shown that pharmacologic modulation of 
glutamate signaling in ER negative, progesterone receptor 
negative, and human epidermal growth factor receptor 2 
(HER2) negative breast cancer cells induces apoptosis, 
inhibits angiogenesis, and reduces tumor cell growth in 
vitro and in vivo [4–6]. These data suggest that riluzole 
may hold promise as a novel therapeutic agent for the 
treatment of cancer including all molecular subtypes of 
breast cancer [1, 4-6, 21].
The cellular and molecular consequences of 
pharmacologic modulation of glutamate signaling 
pathways have not yet been fully elucidated in the setting 
of breast cancer. Nor is the functional target of riluzole 
fully understood. For example, glutamate plays a critical 
role in cellular metabolism. Pharmacologic disruption 
of glutamate levels, e.g. through altered conversion to 
α-ketoglutarate in the citric acid cycle, can subsequently 
alter cell bioenergetics, biochemical equilibrium, 
and metabolic activity affecting cancer cell survival. 
However, the potential role of riluzole in altering cancer 
cell metabolism is currently unknown. Moreover, riluzole 
effects may be tissue-specific due to differing molecular 
alterations and pathway dysregulation. Therefore, a study 
was undertaken to investigate the functional actions of 
riluzole, in comparison to the known noncompetitive 
GRM1 inhibitor BAY 36-7620, on a molecularly diverse 
panel of breast cancer cells. This panel of breast cancer 
cell lines was treated with each glutamate signaling 
modulator, and the functional effects on cell proliferation, 
gene expression, cell cycle alterations, DNA damage, and 
cell metabolism were evaluated.
RESULTS
Breast cancer cell lines express GRM1
ER positive and negative breast cancer cell lines 
were evaluated for GRM1 expression by Western blot 
(Figure 1). Each cell line expressed GRM1 but expression 
was variable across this molecularly distinct set of cell 
lines: MCF-7, MDA-MB-231, and BT-549 had high 
expression of GRM1; T-47D, BT-474, and Hs578T had 
low expression (Table 1).
Riluzole and BAY 36-7620 inhibit breast cancer 
cell growth
GRM1 has previously been reported to play a role 
in breast cancer cell growth and proliferation [1, 4]. To 
determine the effects of these drugs on cell growth, ER+ 
and ER- breast cancer cell lines were treated with either 
riluzole or BAY 36-7620 for 72 h. Both drugs inhibited 
the number of viable cells in all cell lines (Figure 2A and 
2B). IC
50
 values for riluzole and BAY 36-7620 ranged 
from 19.0-62.4 μM and 15.7-41.0 μM, respectively 
(Table 1). BT-474, Hs578T, and BT-549 cells were the 
most sensitive to both drugs while MDA-MB-231 cells 
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were the least sensitive. BAY 36-7620 at the highest 
concentrations completely inhibited cell growth. At the 
highest concentrations evaluated, riluzole inhibited cell 
growth by 70-90% compared to control.
Treatment with riluzole or BAY 36-7620 inhibits 
cell proliferation
Since both drugs reduced cell number, their effect on 
proliferation was determined as measured by 5-ethynyl-
2´-deoxyuridine (EdU) incorporation. The percentage of 
proliferating cells was decreased in each breast cancer 
cell line by riluzole or BAY 36-7620 (Figure 3). However, 
no association between the anti-proliferative effect of 
riluzole or BAY 36-7620 and GRM1 levels was observed. 
T-47D, BT-474, and BT-549 cells were significantly 
more sensitive to BAY 36-7620 than to riluzole at the 
concentration evaluated suggesting that BAY 36-7620 has 
a more potent effect on cell proliferation. Notably, the low 
GRM1-expressors were still very sensitive to riluzole or 
BAY 36-7620 implying that there may be off-target effects 
for each drug.
Riluzole and BAY 36-7620 alter gene expression 
signatures in cell cycle and oncogenic pathways
Gene expression analysis of MCF-7, BT-474, and 
BT-549 cells was done to identify gene sets in pathways 
altered by either drug to better understand their mechanism 
of action. These cell lines were included to compare cells 
with a range of sensitivity to riluzole or BAY 36-7620 with 
BT-549 being the most sensitive and MCF-7 being the least 
sensitive. As BT-549 and BT-474 cells are more sensitive 
to cell death by both drugs, these cell lines were treated 
for 24 h, whereas the less sensitive MCF-7 cells were 
treated for 48 h. Overall, riluzole or BAY 36-7620 induced 
similar gene signature profiles for each of the three cell 
lines as compared to dimethyl sulfoxide (DMSO) control 
(Figure 4A). However, differential expression signatures 
were observed for riluzole as compared to BAY 36-7620. 
For example, BAY 36-7620, but not riluzole, induced the 
cholesterol biosynthesis gene signature in MCF-7 and 
BT-474 cells. Expression signatures for cell cycle genes 
showed significant decreases in gene expression by both 
drugs in comparison to DMSO control in MCF-7 and BT-
549 cell lines (Figure 4A and 4B, Supplementary Table 
1). There are trends of activation of oncogenic pathways 
such as signatures for hypoxia-inducible factor 1-alpha 
(HIF1-α), RAS, and nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) and alteration of 
tumor suppressor pathways such as signatures for p53 and 
phosphatase and tensin homolog (PTEN). There is also 
a trend toward inactivation of the Myc targets signature 
which is consistent with the observed reduction in cell 
proliferation (Figure 3). Regarding metabolic signatures, 
a trend toward up-regulation of TFEB targets is observed 
Figure 1: A panel of breast cancer cell lines expresses GRM1. Estrogen receptor (ER) positive (MCF-7, T-47D, BT-474) and ER 
negative (MDA-MB-231, Hs578T, BT-549) breast cancer cell lines were tested for GRM1 expression by Western blot. C8161 (GRM1+) 
and UACC930 (GRM1 C-terminal truncation) melanoma cells were included as a positive and negative control, respectively, for GRM1 
expression at the predicted molecular weight (MW) of 132 kilodaltons (kDa). β-actin served as a loading control.
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Figure 2: Riluzole and BAY 36-7620 inhibit growth of both hormone receptor positive (MCF-7, T-47D, BT-474) and 
negative (MDA-MB-231, Hs578T, BT-549) breast cancer cell lines. Cells were treated with riluzole (A) or BAY 36-7620 (B) for 
72 h. Relative cell number was measured by MTS assay and normalized relative to vehicle control (DMSO). Data are represented as mean 
+/- SD.
Figure 3: Riluzole and BAY 36-7620 inhibit cell proliferation in both ER+ and ER- breast cancer cell lines. Cells were 
treated with 50 μM riluzole or 50 μM BAY 36-7620 for 72 h. 5-ethynyl-2´-deoxyuridine (EdU) incorporation as a measure of proliferating 
cells was detected by flow cytometry. Data are represented as mean +/- SD. *P < 0.05 compared to DMSO control. **P < 0.005 compared 
to DMSO control. ‡ P < 0.05 for riluzole compared to BAY 36-7620 treatment (right bracket arm) using one-way ANOVA with Bonferroni's 
multiple comparison test.
Table 1: Molecular characteristics and drug response of breast cancer cell lines
Cell line ER status GRM1 expression RiluzoleIC50-μM (SD)*
BAY 36-7620
IC50-μM (SD)
MCF-7 Positive High 34.7 (9.9) 27.7 (5.8)
T-47D Positive Low 32.6 (4.1) 37.1 (7.6)
BT-474 Positive Low 24.2 (4.9) 20.8 (6.6)
MDA-MB-231 Negative High 62.4 (10.9) 41.0 (3.2)
Hs578T Negative Low 19.0 (2.7) 21.0 (2.8)
BT-549 Negative High 24.7 (10.6) 15.7 (1.3)
*Values in parentheses represent +/- standard deviation
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in MCF-7 cells treated with riluzole and BT-549 cells 
treated with either drug, suggesting induction of lysosomal 
biogenesis and activation of autophagy. Riluzole increased 
the cell migration gene signature in MCF-7 cells but 
decreased it in BT-549 cells. It is important to note that 
differences in gene expression profiles across cell lines 
may be due to cell line heterogeneity. BT-474 cells are 
HER2+ and may be under higher replicative stress 
which may contribute to the variability in a subset of the 
expression profiles between cell lines.
Gene microarray results were validated using 
quantitative reverse transcription PCR (qRT-PCR) on 
a subset of genes found to be up- or down-regulated. A 
set of cell cycle regulated genes (CDKN1A, CDKN2C, 
CCNE2) were validated since both riluzole and BAY 36-
7620 induced alterations in expression signatures for cell 
cycle genes and because of the previously observed effects 
of riluzole on G2/M arrest [21]. Additionally, SLC7A11 
gene expression was validated as this gene encodes for the 
glutamate antiporter xCT. Finally, expression of ASNS, a 
gene that encodes for the metabolic enzyme asparagine 
synthetase, was confirmed as glutamate is an important 
metabolic factor. Comparison between microarray analysis 
and qRT-PCR showed that the direction of change in 
gene expression was concordant among all genes tested 
in BT-549 and BT-474 cells and several genes in MCF-
7 cells (Figure 4B and 4C, Supplementary Table 2, 
Supplementary Figure 1). However, the fold changes that 
were dissimilar between the two methods may be, in part, 
due to inherent differences between the methods.
Figure 4: Gene expression signatures are altered by treatment with riluzole or BAY 36-7620. (A) RNA from MCF-7 (48 h 
treatment), BT-474 (24 h treatment), and BT-549 (24 h treatment) cells treated with either 50 μM riluzole or BAY 36-7620 was applied to a 
gene expression microarray. Three biological replicates were used for each condition. Heat map representation of gene expression signatures 
from the average of three biological replicates: significantly upregulated (P< 0.05; red), significantly downregulated (P< 0.05; blue), or no 
significant change (black) compared to expression in cells treated with DMSO control. (B) Graphical representation of a selection of genes 
altered by riluzole or BAY 36-7620 in the gene expression microarray for BT-549 cells compared to DMSO control. (C) A two-step RT-PCR 
was performed on RNA from BT-549 cells for genes up- (SLC7A11, ASNS, CDKN1A) or down-regulated (CDKN2C, CCNE2) by gene 
expression microarray. Gene expression is shown as relative fold change compared to DMSO control. Data are represented as mean +/- SD. 
*P < 0.005 compared to DMSO control.
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Riluzole more strongly induces G2/M cell cycle 
arrest than BAY 36-7620
Effects of riluzole and BAY 36-7620 on cell cycle 
distribution were investigated. Each breast cancer cell line 
treated with riluzole showed a significant dose- and time-
dependent induction of G2/M arrest (Figure 5). BT-474 
and BT-549 cells were most sensitive to riluzole with an 
increase in the sub G1 population as early as 48 h and 24 
h respectively (Figure 5E and 5I). BAY 36-7620 induced 
a more modest G2/M arrest in T-47D, BT-474, MDA-
MB-231, and BT-549 cell lines (Figure 5D-5J) but had no 
effect in MCF-7 cells (Figure 5A and 5B) as compared to 
riluzole. Although both riluzole and BAY 36-7620 inhibited 
proliferation, more pronounced G2/M arrest by riluzole 
may implicate other targets beyond those of BAY 36-7620.
Riluzole but not BAY 36-7620 induces mitotic 
arrest in breast cancer cells
To distinguish whether riluzole or BAY 36-7620 
treatment induces G2 arrest or mitotic arrest in breast 
cancer cells, the fraction of cells with phosphorylation of 
histone H3 was utilized as a marker of mitosis. Riluzole 
significantly increased the number of phospho-H3 stained 
cells compared to control in all cell lines suggesting 
that riluzole induced mitotic arrest (Figure 6A and 6B). 
In contrast, BAY 36-7620 exhibited variable cell line-
dependent effects. BAY 36-7620 significantly decreased 
the number of phospho-H3 stained cells in MCF-7, T-47D 
and BT-549 cells while a modest increase was observed in 
MDA-MB-231 cells (Figure 6A and 6B).
Breast cancer cells treated with riluzole or BAY 36-
7620 were also investigated for changes in known markers 
for mitosis. Riluzole significantly decreased phospho-
cdc2 in MCF-7, T-47D, Hs578T, and BT-549 cells and 
significantly increased cyclin B1 in Hs578T cells with 
a trend toward increase in T-47D, BT-474, and BT-549 
cells (Figure 6C, Supplementary Figure 2). This supports 
a role for riluzole in induction of mitotic arrest. BAY 36-
7620 only decreased phospho-cdc2 in MCF-7, T-47D, 
Hs578T, and BT-549 cells at higher, more cytotoxic 
concentrations and did not increase cyclin B levels (Figure 
6C, Supplementary Figure 2). The effects of riluzole on 
phospho-H3, phospho-cdc2, and cyclin B1 suggest that 
riluzole induces mitotic arrest within G2/M arrest whereas 
Figure 5: Riluzole induces G2/M cell cycle arrest to a greater extent than BAY 36-7620. MCF-7 (A, B), T-47D (C, D), BT-
474 (E, F), MDA-MB-231 (G, H), and BT-549 (I, J) cells were treated with either 25 or 50 μM riluzole or BAY 36-7620 for 24, 48, or 72 h. 
DNA content was measured by flow cytometry. Data are represented as mean +/- SD. *P < 0.05 compared to DMSO control. **P < 0.005 
compared to DMSO control. Representative histograms are shown for 50 μM drug treatment after 72 h for MCF-7 and MDA-MB-231 cell 
lines (K).
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BAY 36-7620 had a minimal effect on both G2/M arrest 
and more specifically mitotic arrest.
DNA damage is observed after treatment with 
BAY 36-7620
DNA damage is known to result in G2/M arrest 
within the cell cycle [22, 23]. To determine whether riluzole 
or BAY 36-7620 induces DNA damage as a potential 
cause of G2/M arrest, phosphorylation of histone H2AX 
(γ-H2AX) was evaluated as a well-described marker of 
DNA damage, specifically DNA double strand breaks. All 
breast cancer cell lines treated with either riluzole or BAY 
36-7620 had an increased percentage of cells positive for 
γ-H2AX foci as detected by immunofluorescence (Figure 
7A). However, BAY 36-7620 induced a significantly more 
robust H2AX phosphorylation than riluzole. Increased 
γ-H2AX nuclear foci after drug treatment can be seen in 
representative images from an ER+ (MCF-7) and ER- 
(MDA-MB-231) cell line (Figure 7B).
Riluzole-induced cell cycle arrest is independent 
of oxidative stress
It has been hypothesized that riluzole induces 
oxidative stress due to reduced antiport of glutamate 
and cystine via xCT, leading to depletion of glutathione 
stores then DNA damage in melanoma cells [24]. To 
evaluate if riluzole or BAY 36-7620 increased oxidative 
stress in breast cancer cells, levels of reactive oxygen 
species (ROS) and total intracellular glutathione (GSH) 
were evaluated. BAY 36-7620 significantly increased 
ROS in T-47D and BT-474 ER+ breast cancer cell 
lines, while riluzole resulted in significantly increased 
ROS only in BT-474 cells (Figure 8A). Although the 
increase in ROS by BAY 36-7620 was not statistically 
significant in MCF-7 cells, the trend was similar to the 
other two ER+ cell lines. When comparing the two 
drugs, the increase in ROS was significantly higher with 
BAY 36-7620 as compared with riluzole. Neither drug 
significantly increased ROS in ER- cells. Interestingly, 
Figure 6: Riluzole induces mitotic arrest in breast cancer cells. ER+ (A) and ER- (B) breast cancer cells were treated with 50 
μM riluzole or 50 μM BAY 36-7620 for 48 h. Cells were stained with an antibody specific to phospho-histone H3 at Ser10 (phospho-H3) as 
a marker for mitosis and detected by flow cytometry. DMSO was used as a vehicle control. *P < 0.05 compared to DMSO control. **P < 
0.005 compared to DMSO control. Data are represented as mean +/- SD. (C) Phospho-cdc2 (Tyr 15; p-cdc2) and cyclin B1 expression were 
measured by Western blot after 24 h (Hs578T, BT-549) or 48 h (MCF-7, T-47D, BT-474, MDA-MB-231) drug treatment. Representative 
blot is shown (Western blot densitometry shown in Supplementary Figure 2). β-actin and cdc-2 served as loading controls for cyclin B1 
and p-cdc2 respectively.
Oncotarget44646www.impactjournals.com/oncotarget
there was a modest decrease in ROS in MDA-MB-231 
treated with BAY 36-7620 and Hs578T ER- cell lines 
treated with either riluzole or BAY 36-7620. Total 
glutathione (GSH) levels decreased after riluzole or 
BAY 36-7620 treatment in BT-474 and Hs578T cells 
while no significant effect was observed in the other cell 
lines (Figure 8B). Both cell lines have relatively low 
GRM1 protein levels suggesting that drug treatment may 
affect other glutamate receptor targets.
To determine whether riluzole-mediated cell cycle 
arrest is dependent on induction of oxidative stress, cells 
were pretreated with the ROS scavenger N-acetyl-cysteine 
(NAC). As a positive control for ROS, MCF-7 cells 
were treated with hydrogen peroxide (H
2
O
2
). This led to 
induction of G2/M cell cycle arrest which was prevented 
by pretreatment with NAC (Figure 8C). However, NAC 
pretreatment did not prevent riluzole-induced G2/M cell 
cycle arrest in MCF-7, T-47D, BT-474, and BT-549 cells 
suggesting that riluzole exerts its effect independent of 
ROS generation (Figure 8D).
Riluzole alters cellular metabolism
Riluzole has been shown to alter intracellular 
glutamate levels. As glutamate is a critical component of 
the citric acid cycle, metabolic alterations were evaluated 
as a possible contributor to riluzole-induced cell cycle 
arrest. BT-474 cells were used because this cell line 
is particularly sensitive to riluzole with respect to cell 
cycle arrest compared to other cell lines tested. Oxygen 
consumption rate (OCR) was evaluated at short and long 
time intervals as a measure of oxidative phosphorylation 
in riluzole-treated cells. OCR was unchanged after 4 
h treatment, but levels of oxidative phosphorylation 
Figure 7: Riluzole and BAY 36-7620 induce DNA damage. (A) Immunofluorescence for γ-H2AX was performed on cell lines 
treated with 50 μM riluzole or 50 μM BAY 36-7620 for 24 h. Positive γ-H2AX staining is shown as a percentage of total cells. DAPI was 
used as a nuclear stain. Data are represented as mean +/- SD. *P < 0.05 compared to DMSO control. **P < 0.005 compared to DMSO 
control. (B) Representative images of MCF-7 and MDA-MB-231 cells with γ-H2AX foci by immunofluorescence.
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significantly decreased after 24 h riluzole treatment 
compared to control suggesting that riluzole inhibits 
oxidative metabolism in this breast cancer cell line (Figure 
9A). To investigate the immediate effect of riluzole on 
oxidative phosphorylation, BT-474 cells were treated with 
riluzole followed by real-time detection of OCR at short 
intervals. Riluzole induced an immediate reduction in 
OCR and inhibition of return to basal OCR levels over the 
time frame evaluated as compared to control (Figure 9B).
To identify which key metabolic pathways were 
altered, water-soluble metabolites from riluzole-treated 
BT-474 cells were measured by liquid chromatography–
mass spectrometry (LC/MS). Cells treated with riluzole 
have a significantly altered metabolic profile, i.e. 
riluzole induced a greater than two-fold increase in the 
cellular levels of several nucleotides and nucleosides 
(Supplementary Table 3). Intermediary nucleoside levels 
are the most significantly increased upon riluzole treatment 
suggesting altered purine and pyrimidine catabolism 
(Figure 9C and 9D). Furthermore, N-carbamoyl-aspartate, 
an intermediate in de novo pyrimidine synthesis, was the 
only metabolite with significantly reduced levels upon 
riluzole treatment suggesting riluzole may inhibit de novo 
pyrimidine synthesis.
DISCUSSION
Incorporation of riluzole into breast cancer treatment 
paradigms has been hampered by a limited understanding 
of its mechanism of action. In this study, a pharmacologic 
approach was undertaken to investigate the antitumor 
effects of riluzole in a panel of human breast cancer cell 
lines and compared to the effects of the known glutamate 
receptor antagonist BAY 36-7620. Treatment with either 
drug produced cell line-dependent effects on markers for 
proliferation, cell cycle, and DNA damage. Both drugs 
inhibited cell growth and cell number while altering 
expression of genes involved in cell cycle regulation and 
oncogenic pathways. While riluzole and BAY 36-7620 
both induce cell death, they have differential effects within 
cell cycle. Whereas riluzole induced cell death with mitotic 
arrest, BAY 36-7620 caused cell death without substantial 
Figure 8: Riluzole-mediated G2/M arrest is independent of induction of oxidative stress. Breast cancer cell lines treated 
with 50 μM riluzole or 50 μM BAY 36-7620 for 24 h were evaluated for levels of reactive oxygen species (ROS) (A) and total intracellular 
glutathione (GSH) (B). Relative fold change was compared to DMSO control. *P < 0.05 compared to DMSO control. **P < 0.005 
compared to DMSO control. Cell cycle distribution (represented as the percentage of cells in G2/M) was detected by flow cytometry in cells 
pretreated with 5mM N-acetyl-cysteine (NAC) followed by the addition of 25 μM H
2
O
2
 (C) or 50 μM riluzole (D). *P < 0.05 compared to 
control. **P < 0.005 compared to control. ‡ P < 0.005 for NAC+H
2
O
2
 compared to H
2
O
2
 treatment alone. Not significant (n.s.). Data are 
represented as mean +/- SD.
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effect on cell cycle. Riluzole induced significant metabolic 
changes in the cell including decreased oxidative 
phosphorylation and alteration of cellular metabolite levels 
suggesting a novel role for riluzole in cell metabolism. 
Some cell lines showed differential sensitivity to either 
riluzole or BAY 36-7620. These data support distinct drug-
induced mechanisms of cell cycle inhibition leading to cell 
death.
Riluzole-induced DNA damage in breast cancer cell 
lines was variable and cell line-specific, an observation 
consistent with that in melanoma cells [24]. However, 
BAY 36-7620 had a significantly more robust effect as 
compared to riluzole. Genomic variability between breast 
cancer cell lines may influence susceptibility to riluzole. 
One such area of speculation includes TP53 mutational 
status or HER2 status that place cells under replicative 
stress. Riluzole did not induce DNA damage in MCF-
7 cells (TP53 wildtype) whereas moderate induction of 
DNA damage occurred in the majority of TP53 mutant cell 
lines. In contrast, BAY 36-7620 had a more universal DNA 
damaging effect on all cell lines tested, again suggesting a 
distinct mechanism from riluzole. Interestingly, riluzole-
induced mitotic arrest was more prominent in TP53-
mutated cell lines as compared to TP53 wildtype MCF-7 
cells suggesting that loss of p53 checkpoint activity may 
lead to mitotic catastrophe in TP53 mutant cells. Given 
the paucity of TP53 wildtype breast cancer cell lines, this 
relationship is difficult to confirm. Further exploration 
of the role of p53 may enlighten any potential role in 
response to riluzole. In addition to TP53 mutations, 
alterations in other genes involved in the DNA damage 
response or other pathways may also sensitize cells to 
riluzole-induced DNA damage. For example, BT-474 
cells have alterations in BRCA2, ATM, and PARP1 that 
may predispose these cells to increased DNA damage by 
riluzole. Also, BT-474 cells are Her2 overexpressing and 
have a higher mitotic rate which may induce replicative 
stress upon treatment with riluzole. Further exploration 
Figure 9: Riluzole inhibits oxidative phosphorylation and alters cellular metabolism. (A) BT-474 cells were treated with 
control (DMSO) or 50 μM riluzole for 4 h or 24 h. Oxygen consumption rates (OCR) were measured on the XF analyzer and are shown 
relative to basal levels. *P < 0.05 compared to DMSO control. (B) Basal OCR was measured in BT-474 cells at time 0 followed by 
treatment with DMSO or 50 μM riluzole. OCR was measured at 15 min intervals after treatment. Data are represented as mean +/- SD. (C, 
D) Cellular metabolite analysis by LC/MS was performed on BT-474 cells treated with 50 μM riluzole for 24 h and normalized to DMSO 
control (see Supplementary Table 3 for complete list of relative fold changes). Components of purine (C) and pyrimidine (D) metabolism 
altered by riluzole are shown (fold change in parenthesis).
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of drug response in genetically engineered cell lines may 
help to better delineate these relationships.
While others have found correlations between 
riluzole-induced DNA damage and GRM1 expression 
in melanoma cell lines [24], there was no apparent 
correlation between GRM1 level and drug response to 
riluzole in these breast cancer cell lines. Moreover, riluzole 
was still effective in cell lines with the lowest GRM1 
expression suggesting that riluzole may affect non-GRM1 
targets. Similarly, Speyer et al. [25] found that genetically 
altering GRM1 expression in breast cancer cells did not 
affect response to riluzole. These data and that by others 
are consistent with the hypothesis that riluzole may have 
effects that are independent of direct signaling through 
GRM1. Neither data eliminate a possible role for other 
glutamate receptors as mediators of riluzole response in 
these cell lines and would require further study.
Others have shown that riluzole alters redox 
homeostasis as a mechanism for DNA damage and cell 
death in melanoma cells in vitro [24]. Increased ROS and 
reduced GSH were observed in a subset of riluzole-treated 
breast cancer cell lines suggesting alteration of the redox 
state of some cell lines. However, the antioxidant NAC 
was unable to inhibit riluzole-induced cell cycle arrest 
suggesting that either these two events are not coupled or 
that DNA damage occurs as a later event. While riluzole 
induced oxidative stress, this seemed to be independent of 
its effect on cell cycle in breast cancer cells.
Riluzole has been shown to indirectly inhibit GRM1 
activity in melanoma [13]. The data presented here suggest 
that there are distinct drug-specific effects between riluzole 
and BAY 36-7620 in breast cancer cells. Further, these 
data are consistent with effects that may be independent 
of direct signaling through GRM1. These effects include 
altered oxidative metabolism and levels of cellular 
metabolites. Riluzole effect on other glutamate receptors 
or pathways regulated by glutamate cannot be ruled out. 
However, ammonia levels, which can be produced by 
glutamate metabolism, were unchanged by riluzole (data 
not shown) suggesting that it does not induce ammonia 
toxicity as its mechanism of action. As other pathways are 
glutamate-dependent, including but not limited to amino 
acid biosynthesis and lipid synthesis, additional research 
into the effects of riluzole on these pathways is warranted.
Riluzole also altered precursors or derivatives of 
nucleotides that compose DNA. As such, altered DNA 
biosynthesis pathways remain a possible target. It has 
been shown that incorporation of precursor nucleotides in 
DNA leads to stalled replication forks and ultimately cell 
cycle arrest and death [26]. Alternatively, an increase in 
nucleotide catabolism may not be a direct effect of riluzole 
treatment, but a consequence of mitotic arrest. Riluzole-
induced mitotic arrest shifts the cell population towards 
an increase in the fraction of cells in G2/M. Cells in G2/M 
may increase the catabolism of nucleotides that are not 
further needed for DNA synthesis. The observed increase 
in nucleotide/nucleoside levels may reflect cell cycle-
specific differences.
Riluzole has been studied in Phase II clinical 
trials for the treatment of patients with stage III and IV 
melanoma with 42% of patients exhibiting stable disease 
[27]. As an FDA-approved drug for other indications, 
riluzole could be quickly moved into trials for the 
treatment of breast cancer based on its antitumor effects 
in preclinical models. Understanding the mechanistic 
effects provides a rationale to explore the use of riluzole 
alone or in combination with other anti-cancer therapies. 
Breast cancer subtypes with high replicative stress (e.g. 
TP53 mutation, MYC amplification, high mitotic index) 
or those with DNA repair defects (e.g. triple negative 
breast cancers, BRCA-related breast cancers) may 
represent markers for more suitable patient selection for 
riluzole-based regimens. However, this would require 
additional biomarker evaluation to determine association 
with riluzole sensitivity. Based on this study and others, 
further development of riluzole and direct glutamate 
signaling modulators for preclinical and clinical studies 
is warranted.
MATERIALS AND METHODS
Cell lines and culture
MCF-7, T-47D, BT-474, MDA-MB-231, Hs578T, 
and BT-549 breast cancer cell lines (Charles River 
Laboratories, Inc, New York, NY; ATCC, Manassas, VA) 
were maintained in Dulbecco's Modified Eagle's medium 
(DMEM; Sigma Aldrich, St. Louis, MO) plus 10% fetal 
bovine serum (FBS) and 1% penicillin-streptomycin (Life 
Technologies, Grand Island, NY) at 37°C in a humidified 
atmosphere containing 5% CO
2
. All cell lines were 
authenticated by the Gene Expression and Genotyping 
Core Facility at the University of Florida Interdisciplinary 
Center for Biotechnology Research using the established 
STR profiling system.
Reagents and antibodies
Riluzole hydrochloride (Tocris Bioscience, Bristol, 
UK) and BAY 36-7620 (Tocris Bioscience, Bristol, UK) 
were dissolved in DMSO. GRM1 primary antibody is 
specific to the C-terminal region of human GRM1α and 
was used at a dilution of 1:2000 for Western blotting 
(catalog number 36350002; Novus Biologicals, Littleton, 
CO). Additional primary antibodies for Western blotting 
or immunofluorescence include monoclonal anti-ß-actin 
clone AC-15 (Sigma Aldrich, St. Louis, MO); phospho-
cdc2 (Tyr15), cyclin B1, phospho-histone H2AX (Ser139) 
(Cell Signaling, Danvers, MA). Primary antibodies for 
flow cytometry include phospho-histone H3 (Ser10) 
rabbit monoclonal (Alexa Fluor® 488 conjugate), histone 
H3 rabbit monoclonal (Alexa Fluor® 647 conjugate), 
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rabbit monoclonal IgG isotype control (Alexa Fluor® 488 
conjugate), rabbit monoclonal IgG isotype control (Alexa 
Fluor® 647 conjugate) (Cell Signaling, Danvers, MA).
Western blot analysis
Cell lysates were prepared using RIPA buffer 
(Sigma Aldrich, St. Louis, MO) with Protease Inhibitor 
Cocktail and Phosphatase Inhibitor Cocktail 2 and 3 
(Sigma Aldrich, St. Louis, MO) and centrifugation at 
12,000 X g for 15 min at 4°C. Protein concentration was 
determined using the Bradford protein assay reagent (Bio-
Rad, Hercules, CA). Lysates were separated by 4-20% 
gradient sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) under reducing conditions. 
Protein was transferred onto a polyvinyl difluoride 
(PVDF) membrane. Membranes were incubated overnight 
at 4°C with primary antibody followed by incubation with 
horseradish peroxidase secondary antibody. Enhanced 
chemiluminescence (ECL) reagent was added to the 
membrane according to the manufacturer's protocol (Pierce 
Biotechnology Inc., Rockford, IL). Chemiluminescence 
was detected on the ChemiDoc™ Imaging System, and 
densitometry was performed using the Image Lab software 
(Bio-rad, Hercules, CA)
Drug sensitivity assay
Cells were seeded in 96 well plates and allowed to 
attach overnight. Cells were then treated with increasing 
concentrations of drug. After 72h of drug treatment, 
MTS reagent (Promega, Madison, WI) was added and 
cells were incubated at 37°C for 2-4 h. Absorbance was 
measured at 490 nm using a Wallac 1420 Victor3 plate 
reader (Perkin Elmer, Waltham, MA). Viability was 
expressed as a percentage of control by dividing the 
absorbance of each treated sample by the average of the 
untreated controls.
Cell proliferation assay
Cells were seeded in 6 well plates and allowed to 
attach overnight. Cells were then treated with drug for 
72 h. EdU was added at a final concentration of 10 μM 
at 48 h drug treatment. Cell number was determined 
using the Vi-CELL Cell Viability Analyzer (Beckman 
Coulter, Indianapolis, IN). Equal cell numbers were fixed, 
permeabilized, and stained according to manufacturer’s 
instructions (Click-iT® EdU Alexa Fluor® 488 Flow 
Cytometry Assay Kit; Life Technologies, Grand Island, 
NY). Percentage of proliferating cells was assessed by 
flow cytometry at an excitation wavelength of 488 nm. 
Cells without EdU labeling were used as a negative 
control for proper gating conditions. Data were analyzed 
using CXP software (Cytomics FC 500 Series; Beckman 
Coulter, Indianapolis, IN).
Gene expression analysis
MCF-7 cells were treated with 50 μM riluzole or 
BAY 36-7620 for 48h. BT-474 and BT-549 cells were 
treated for 24h due to rapid entry of cells into subG1. 
Total RNA was purified with RNeasy mini kit following 
manufacturer’s protocol (Qiagen, Germantown, MD). 
RNA was subjected to DNase treatment to remove 
contaminating DNA. The Human Genome U133A 2.0 
Array was used to measure gene expression changes 
from drug treatment compared to DMSO control. Three 
independent replicates were used for each condition. 
For analysis, raw CEL files were processed using the 
justRMA function in R Bioconductor, obtaining log2 
expression values. Gene expression signatures were 
analyzed using Gene Set Enrichment Analysis [28], 
obtaining a quantification of the statistical significance 
for upregulation (P+) or downregulation (P-) for each 
signature and sample pair. A sample was said to have a 
signature significantly upregulated if P+ < 0.05 (red), 
significantly downregulated if P- < 0.05 (blue), and no 
significant change otherwise (black). For microarray 
validation, RNA from cells treated with DMSO, 50 μM 
riluzole, or 50 μM BAY 36-7620 was reverse transcribed 
using the Taqman Reverse Transcription kit following 
manufacturer’s protocol (Thermo Fisher Scientific, 
Waltham, MA). Pre-designed Taqman assays for genes 
validated were used to perform quantitative PCR on the 
complementary DNA. The RPLP0 gene was used as a 
housekeeping gene control. Results are shown as relative 
fold change of gene expression compared to DMSO 
control treatment using the delta delta Ct method.
Cell cycle analysis
Cells grown overnight were then treated with drug 
for 48 and 72 h. All cells were collected by trypsinization 
and cell number was determined using the Vi-CELL Cell 
Viability Analyzer (Beckman Coulter, Indianapolis, IN). 
Single cell suspensions with equal cell number were 
prepared. Cells were fixed with absolute ethanol and 
incubated overnight at -20°C then stained with 10 μg/ml 
propidium iodide and 100 μg/ml RNase A in phosphate-
buffered saline (PBS; Sigma Aldrich, St. Louis, MO). Cell 
cycle distribution was assessed by flow cytometry and 
analyzed using CXP software (Cytomics FC 500 Series; 
Beckman Coulter, Indianapolis, IN).
Histone H3 phosphorylation
Cells were grown overnight and then treated with 
drug for 48 and 72 h. Cell number was determined using 
the Vi-CELL Cell Viability Analyzer (Beckman Coulter, 
Indianapolis, IN). Paraformaldehyde was added to suspended 
cells to a final concentration of 4% for 10 min at 37°C. Cells 
were permeabilized with 90% methanol, incubated on ice 
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for 30 min, and then washed twice with incubation buffer 
(5 mg/ml of BSA in PBS). Cells were co-stained for 1 h 
with phospho-histone H3 (Alexa Fluor® 488) and histone H3 
(Alexa Fluor® 647) antibodies, evaluated by flow cytometry, 
and analyzed using CXP software. Unstained and single 
stained controls were used to gate the cells.
γ-H2AX immunofluorescence
Cells were grown in chamber slides and then treated 
with drug for 24 h. Paraformaldehyde was added to cells 
to a final concentration of 4%. Cells were permeabilized 
with 0.5% Triton X-100 for 10 min. Primary antibody 
to γ-H2AX was added to cells in 5% goat serum in PBS 
(blocking buffer) for 1 h. Cells were washed with PBS and 
incubated with fluorescein (FITC)-conjugated secondary 
antibody in blocking buffer for 1 h. Cells were mounted 
with ProLong Diamond Antifade Mountant with DAPI 
(Life Technologies, Grand Island, NY) nuclear stain 
and visualized using the Nikon Eclipse Ti fluorescent 
microscope. Cells positive for γ-H2AX foci were counted 
from four independent fields.
Reactive oxygen species (ROS) detection
Single cell suspensions of 24 h drug-treated 
cells were incubated with CELLROX green reagent 
(Life Technologies, Grand Island, NY) for 45 min at 
37°C. Oxidation-induced fluorescence was detected 
by flow cytometry as a measure of ROS and corrected 
for background autofluorescence. For ROS protection 
experiments, cells were pretreated with 5 mM N-acetyl-
cysteine (NAC; Sigma Aldrich, St. Louis, MO) for 1 h 
followed by treatment with drug.
Intracellular glutathione (GSH) measurement
Cells were treated with drug for 24 h and then 
harvested. Cell pellets were then lysed with 10mM 
hydrochloric acid followed by two freeze thaws. Total 
intracellular glutathione was measured following 
manufacturer’s instructions (GSSG/GSH Quantification 
Kit, Dojindo Molecular Technologies, Rockville, MD).
Oxygen consumption rate measurement
Oxygen consumption rate (OCR) was measured 
using the Extracellular Flux Analyzer (XF24, Seahorse 
Bioscience). For long-term treatments, BT-474 cells were 
grown in normal growth media overnight in XF24 plates. 
Cells were then treated with DMSO control or 50 μM 
riluzole for 4 or 24 h. Media was replaced with DMEM 
without sodium bicarbonate or FBS and incubated for 1 h. 
Basal OCR measurements were taken in DMEM without 
sodium bicarbonate or FBS. For short-term treatments 
(OCR measurements immediately after injection of 
DMSO or 50 μM riluzole), cells were grown in normal 
growth media overnight in XF24 plates then replaced with 
DMEM without sodium bicarbonate or FBS and incubated 
for 1 h. OCR measurements were taken at time 0, then 
every 15 min after injection of DMSO or 50 μM riluzole.
Cellular metabolite analysis by LC/MS
BT-474 cells were treated with DMSO or 50 μM 
riluzole for 24 h. Water-soluble metabolites were extracted 
and analyzed by LC/MS as previously described [29]. 
Metabolite measurements were normalized to cell number.
Statistical analysis
All graphical data are represented as mean +/- standard 
deviation (SD). For riluzole or BAY 36-7620 treatments, 
unpaired, two-tailed Student’s t-test was used to calculate 
the P value of the difference between control (DMSO) and 
treated cells from three independent experiments where 
a P value of less than 0.05 was considered statistically 
significant. For comparison of riluzole and BAY 36-7620, 
one way analysis of variance (ANOVA) with Bonferroni's 
multiple comparison test was used to calculate statistical 
significance between groups. For comparison of cellular 
metabolite levels between control and riluzole, t-test with 
Bonferroni correction was used where a P value of less than 
0.05 was considered statistically significant.
Abbreviations
ANOVA: analysis of variance; ASNS: asparagine 
synthetase (glutamine-hydrolyzing); CCNE2: cyclin 
E2; CDKN1A: cyclin dependent kinase inhibitor 1A; 
CDKN2C: cyclin dependent kinase inhibitor 2C; CNS: 
central nervous system; DMEM: Dulbecco's Modified 
Eagle's medium; DMSO: dimethyl sulfoxide; EdU: 
5-ethynyl-2´-deoxyuridine; ER: estrogen receptor; 
ERK: extracellular signal–regulated kinase; GRM1: 
metabotropic glutamate receptor 1; GSH: intracellular 
glutathione; H
2
O
2
: hydrogen peroxide; γ-H2AX: 
phosphorylation of histone H2AX; HER2: human 
epidermal growth factor receptor 2; HIF1-α: hypoxia-
inducible factor 1-alpha; LC/MS: liquid chromatography-
mass spectrometry; MAPK: mitogen-activated protein 
kinase; MW: molecular weight; NAC: N-acetyl-cysteine; 
NFκB: nuclear factor kappa-light-chain-enhancer of 
activated B cells; OCR: oxygen consumption rate; PBS: 
phosphate-buffered saline; PKC: protein kinase C; PLC: 
phospholipase C; PTEN: phosphatase and tensin homolog; 
PVDF: polyvinyl difluoride; qRT-PCR: quantitative 
reverse transcription PCR; ROS: reactive oxygen species; 
SD: standard deviation; SDS-PAGE: sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis; SLC7A11: 
solute carrier family 7 member 11; TFEB: transcription 
factor EB; TGF beta: transforming growth factor beta; 
xCT: x-C-type transporter
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